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Abstract: Botulinum neurotoxins (BoNTs) comprise seven distinct serotypes that inhibit 
the release of neurotransmitter across neuromuscular junctions, resulting in potentially fatal 
flaccid  paralysis.  BoNT  serotype  A  (BoNT/A),  which  targets  synaptosomal-associated 
protein  of  25kDa  (SNAP-25),  is  particularly  long-lived  within  neurons  and  requires  a 
longer time for recovery  of neuromuscular function. There are  currently no treatments 
available to counteract BoNT/A after it has entered the neuronal cytosol. In this study, we 
examined  the  ability  of  small  molecule  non-peptidic  inhibitors  (SMNPIs)  to  prevent 
SNAP-25 cleavage post-intoxication of neurons. The progressive cleavage of SNAP-25 
observed  over  5  h  following  1  h  BoNT/A  intoxication  was  prevented  by  addition  of 
SMNPIs. In contrast, anti-BoNT/A neutralizing antibodies that strongly inhibited SNAP-25 
cleavage  when  added  during  intoxication  were  completely  ineffective  when  added  
post-intoxication.  Although  Bafilomycin  A1,  which  blocks  entry  of  BoNT/A  into  the 
cytosol  by  preventing  endosomal  acidification,  inhibited  SNAP-25  cleavage  
post-intoxication, the degree of inhibition was significantly reduced versus addition both 
during and after intoxication. Post-intoxication application of SMNPIs, on the other hand, 
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was nearly as effective as application both during and after intoxication. Taken together, 
the results indicate that competitive SMNPIs of BoNT/A light chain can be effective within 
neurons post-intoxication. 
Keywords:  botulinum  neurotoxin;  small  molecule  non-peptidic  inhibitor;  neutralizing 
antibody; Bafilomycin A1 
 
1. Introduction 
Botulinum  neurotoxins  (BoNTs)  are  the  most  potent  of  known  biological  toxins  [1].  By 
proteolytically  cleaving  components  of  the  soluble  N-ethylmaleimide-sensitive  factor  attachment 
protein receptor (SNARE) complex, BoNTs impair neuronal synaptic vesicle fusion, thus preventing 
neurotransmission across neuromuscular junctions [2]. This leads to the flaccid paralysis associated 
with the disease state botulism. Of key importance, once diaphragm and external intercostal muscles 
are paralyzed due to BoNT poisoning, death by suffocation results unless critical care intervention is 
implemented [3]. BoNTs are listed as category A biothreat agents by the Centers for Disease Control 
and Prevention, with the potential to be delivered by various routes [1,4], which could result in a  
large-scale outbreak that would overwhelm our current health care system. 
There are seven known BoNT serotypes (designated A–G) [2]. All possess a zinc metalloprotease 
component, referred to as the light chain (LC), with each serotype targeting a different and specific 
peptide  bond  in  one  or  more  of  three  SNARE  proteins.  BoNT  serotypes  A,  C,  and  E  cleave 
synaptosome-associated protein of 25 kDa (SNAP-25). BoNT serotype C also cleaves syntaxin. BoNT 
serotypes  B,  D,  F,  and  G  cleave  synaptobrevin  [2].  Of  the  seven  serotypes,  BoNT  serotype  A 
(BoNT/A) persists the longest within neurons [5] and likewise requires the longest time for recovery of 
neuromuscular function. This long duration of activity has made BoNT/A the serotype of choice for 
many  medical  applications  (such  as  the  treatment  of  strabismus,  cervical  dystonia,  and  
blepharospasm)  [6,7],  as  well  as  the  cosmetic  reduction  of  facial  wrinkles  [8].  Consequently,  the 
clinical value of BoNT/A has made vaccination a less desirable option for preventing botulism, as 
vaccination would neutralize the potential therapeutic benefits of the enzyme. However, the increasing 
use of BoNT/A in clinical applications also carries with it a heightened risk of accidental overdose. In 
addition, intentional misuse of BoNT/A for bioterrorism remains a concern. For these reasons, the 
discovery and development of therapeutics to counter BoNT/A intoxication is of particular importance. 
The current treatment for BoNT intoxication (botulism) consists of anti-toxin therapy [3]. Specifically, 
antibodies are administered that bind to BoNT and aid in clearing it from the bloodstream [3], thereby 
preventing further entry of the toxin into neurons. However, once BoNT/A (or any BoNT) has entered 
the neuronal cytosol, it is inaccessible to these antibodies, rendering antitoxin treatment ineffective 
against  the  persistent  cleavage  of  SNARE  proteins  [9].  In  severe  cases,  the  only  recourse  after  
BoNT-induced paralysis manifests is mechanical ventilation to keep individuals with botulism alive 
until  recovery,  which  can  take  several  months.  In  a  documented  case  of  cosmetic  injection  with 
concentrated and unlicensed BoNT/A, one patient required nearly 6 months of ventilator support to 
survive [10]. This patient did not receive antitoxin until more than a week after exposure to the toxin. Toxins 2011, 3                         
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A second patient, who was injected with the same unlicensed BoNT/A and had a similar serum toxin 
level, received antitoxin 3 days after exposure and, in contrast, was able to be taken off ventilator 
support after little more than a month [10]. Although this example demonstrates the efficacy of the 
antitoxin  when  administered  soon  after  intoxication,  it  also  demonstrates  that  the  window  of 
opportunity  for  effective  treatment  with  antitoxin  is  relatively  narrow.  Hence,  the  search  for  
small-molecule non-peptidic inhibitors (SMNPIs) of BoNT/A has been driven by the hypothesis that 
such  inhibitors,  unlike  anti-BoNT  antibodies,  will  possess  the  ability  to  counter  BoNT/A  LC 
enzymatic activity within the neuronal cytosol. 
While cell-free biochemical assays are useful for the initial selection of compounds that inhibit 
BoNT/A LC enzymatic activity, potent inhibition in these assays does not guarantee effectiveness in 
the  neuronal  cytosol.  In  contrast,  cell-based  assays  can  be  used  to  test  the  post-intoxication 
intracellular efficacy of inhibitors of BoNT/A by intoxicating cells and rinsing away the remaining 
extracellular toxin before adding SMNPI. In this study, this assay was used to demonstrate the ability 
of two SMNPIs, NSC 95654 and NSC 104999, to prevent BoNT/A induced cleavage of SNAP-25 
after intoxication of neurons. 
2. Materials and Methods 
2.1. Neuronal Cell Culture  
Ventral  spinal  cords  were  isolated  from  day  6  embryonic  chicken  embryos  (Charles  River 
Laboratories,  North  Franklin,  CT)  and  cultured  by  the  method  of  Kuhn  [11]  as  previously  
described [12]. Briefly, spinal cords were removed from the embryos and the dorsal halves trimmed 
away.  After  trypsinization  for  25  min,  the  cells  were  dissociated  by  trituration  and  pre-plated  in 
Dulbecco’s  modified  Eagle’s  medium  for  1  h  to  enrich  the  neuronal  population  by  adherence  of  
non-neuronal cells to the culture dish. Cells remaining in suspension were centrifuged for 6 min at 
1250 rpm, resuspended in Liebowitz’s L15 medium with 10% fetal bovine serum and N3 supplements, 
and plated onto 6-well culture plates that were first coated with poly-L-lysine (1 mg/mL overnight), 
and then with laminin (7–10 μg/mL for 3–4 h). Neurons were incubated overnight at 37 ° C in 5% CO2 
before use in the experiments. 
2.2. BoNT/A and Antagonists 
BoNT/A was purchased from Metabiologics Inc. (Madison, WI). NSC 95654 and NSC 104999 
were  obtained  from  the  National  Cancer  Institute’s  Open  Repository.  Stock  solutions  of  these 
compounds were prepared at 10 µM in DMSO and diluted to final concentrations as indicated in cell 
culture medium. Anti-BoNT/A neutralizing antibodies (6E10-10 and 4A2-4) were produced in the U.S. 
Army Medical Research Institute of Infectious Diseases [13] and were previously shown to be highly 
effective  inhibitors  of  BoNT/A  when  applied  together  with  the  toxin  to  chick  motor  neuron  
cultures [12]. Results with each of the two antibodies were similar and were thus pooled for purposes 
of  graphing  and  statistical  analysis.  Bafilomycin  A1  was  purchased  from  Tocris  bioscience  
(Ellisville, MO). 
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2.3. Western Blot Analysis 
Cells were gently scraped and collected into tubes. The tubes were centrifuged, then supernatant 
was removed and replaced with 30 µL of lysis buffer. After overnight storage at −80 ° C, tubes were 
thawed, vortexed briefly, and incubated on ice for 10 min. Lysates were centrifuged at high speed at  
4 ° C for 30 min to remove debris. Total protein was measured by the Bradford assay. 12% gels were 
used for SDS PAGE and proteins were blotted onto PVDF membranes. Western blots were probed 
with a 1:2500 dilution of SMI-81 anti-SNAP-25 antibody (Covance Research Products Inc., Berkeley, 
CA) and 1:20,000 horseradish peroxidase (HRP)-conjugated goat anti-mouse (Pierce, Rockford, IL). 
Western  blots  were  developed  using  a  chemiluminescent  substrate  and  imaged  with  a  BioRad 
Versadoc  system.  Protein  bands  were  quantitated  by  densitometry  with  Quantity  One  software 
(BioRad, Hercules, CA).  
2.4. In Vitro Evaluation of Small-Molecule Inhibitors 
Inhibition of BoNT/A LC metalloprotease activity by NSC 95654 and NSC 104999 in vitro was 
measured  employing  an  HPLC-based  assay  developed  by  Schmidt  and  Bostian  [14].  In  brief  ,  a 
synthetic N-terminal acetylated, C-terminal aminated peptide (New England Peptide, Gardner, MA) 
corresponding to residues 187–203 of SNAP-25 was used as the substrate for recombinant BoNT/A 
LC (List Laboratories, Campbell, CA). Assays were conducted by diluting peptide substrate (100 µM) 
and SMNPIs (1–30 µM) in a buffered solution (40 mM HEPES (pH 7.3), 0.05% Tween 20, 0.5 mg/mL 
bovine serum albumin, 1 mM dithiothreitol, and 50 µM ZnCl2) and initiating reactions by adding 
BoNT/A LC. After 10 min, the reactions were quenched by adding trifluoroacetic acid, and analyzed 
by reverse-phase HPLC. All HPLC measurements were conducted on a Dionex Summit (Sunnyvale, 
CA) HPLC system equipped with a dual wavelength UV/Vis absorbance detector and used a c18 
reverse phase column (3 μm, 10 cm ×  2.1 mm) obtained from Supelco/Sigma-Aldrich (St. Louis, MO). 
IC50  values  were  determined  by  measuring  BoNT/A  LC  activity  at  nine  different  SMNPI 
concentrations, as well as in the absence of SMNPI. The SMNPI concentrations in these measurements 
were determined by estimating the IC50 value and moving in 0.5 log increments in either direction  
of  the  estimated  value.  The  resulting  kinetic  data  were  then  fit  to  the  Langmuir  isotherm,  
Vi/Vo = 1/1 + ([I]/IC50)
h, using nonlinear regression analysis, to obtain Ki values. All reported values 
are averages of at least four independent experiments. 
3. Results and Discussion 
Previous research [15] led to the identification of NSC 104999, a terephthalamide-based SMNPI of 
the BoNT/A  LC metalloprotease  (Figure 1). As  part of the current  study, various analogs  of this 
SMNPI chemotype were obtained and examined for in vitro potency employing an HPLC-based assay. 
Of the examined analogs, NSC 95654 (Figure 1), was found to be substantially more potent in vitro  
(Ki = 1.80 ±  0.18 µM) than either NSC 104999 (Ki = 8.52 ±  0.53 µM ) or the previously reported [16] 
BoNT/A LC inhibitor NSC 240898 (Ki = 10.5 ±  1.10 µM). The higher potency of NSC 95654 suggests 
that  the  synthetic  modification  of  terephthalamide-based  SMNPIs  can  be  used  to  increase  the 
inhibitory potency of this chemotype. Like NSC 240898, NSCs 95654 and 104999 are competitive Toxins 2011, 3                         
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inhibitors that do not act via Zinc (Zn
++) chelation, as increasing concentrations of Zn
++ (from 5 to  
50 µM) had no effect on the ability of the SMNPIs to inhibit BoNT/A LC activity in an in vitro,  
HPLC-based assay (data not shown). 
Figure 1. Chemical structures and Ki values for NSC 95654 and NSC 104999. 
 
Consistent with in vitro results, a preliminary analysis in which chick spinal motor neurons were 
incubated for 3 h with 10 nM BoNT/A showed substantial and dose-dependent protection against 
SNAP-25 cleavage when co-incubated with NSC 95654 (Figure 2). These preliminary results indicated 
that NSC 95654 was much more effective (approximately twofold) at inhibiting SNAP-25 cleavage in 
a cell-based assay than the previously reported NSC 240898 [16]. However, co-incubation of cells 
with  BoNT/A  and  SMNPI  does  not  demonstrate  conclusively  that  the  enzyme  is  being  inhibited  
post-intoxication (i.e., after it has already entered the neuronal cytosol). Because an SMNPI would be 
of greatest clinical value as a therapeutic if it is able to inhibit, within the neuronal cytosol, the ongoing 
cleavage of SNARE proteins by BoNT (i.e., to complement anti-toxin treatment, which helps clear 
BoNT from the bloodstream), we performed detailed studies to determine if NSC 95654 could prevent 
BoNT/A mediated SNAP-25 cleavage when administered to neurons post-intoxication. To examine the 
ability  of  NSC  95654  to  protect  SNAP-25  in  neurons  post-intoxication,  we  first  determined  the 
experimental  parameters  necessary  to  detect  the  on-going  cleavage  of  SNAP-25  that  occurs  after 
BoNT/A has been washed from the surrounding medium. Casual observation suggested that NSC 
95654 was well tolerated by cells over a period of several hours, but that some cell death occurred after 
overnight incubation. Therefore, we wished to minimize cytotoxicity by minimizing post-intoxication 
incubation  time.  To  this  end,  embryonic  chick  spinal  motor  neurons  were  incubated  with  10  nM 
BoNT/A for 1 h, and then washed three times with fresh medium. Cells were collected for Western 
blot analysis of intact and cleaved SNAP-25 either shortly after the removal of BoNT/A or at 1 h 
intervals up to 5 h. As expected based on the previously reported persistence of BoNT/A LC protease 
activity within cells [9], we observed progressive cleavage of SNAP-25 after residual BoNT/A had 
been washed from the medium surrounding the cells (Figure 3, A and C). One way analysis of variance 
(ANOVA) revealed significant differences (P = 0.014) in SNAP-25 cleavage over time. The degree of 
SNAP-25 cleavage was statistically significant by 4 and 5 h after removal of BoNT/A (P = 0.039 and 
P = 0.015, respectively; pairwise comparison with the 0 h timepoint by Tukey Test). In contrast, when 
40 µM NSC 95654 was added to the cells immediately after residual BoNT/A was fully rinsed away, Toxins 2011, 3                         
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no statistically significant additional SNAP-25 cleavage was detected (P = 0.894, one way ANOVA) 
over the course of 5 h (Figure 3B,D). Comparison of percentage intact SNAP-25 in the absence versus 
presence of  NSC 95654 at  5 h post-intoxication demonstrated  a statistically significant  difference  
(P = 0.023; t-test), further indicating that 5 h was sufficient to detect post-intoxication inhibition. 
Based on these results, subsequent experiments were performed by intoxicating cells with BoNT/A for 
1 h and collecting cells for Western blot analysis 5h after residual BoNT/A was thoroughly rinsed from 
the culture medium. 
Figure 2. Inhibition of BoNT/A-mediated SNAP-25 cleavage during co-incubation with 
various  concentrations  of  NSC  95654.  Embryonic  chick  spinal  motor  neurons  were 
incubated for 3 h in 10 nM BoNT/A and 0–40 µM NSC 95654. Western blotting was 
performed  to  reveal  amounts  of  cleaved  and  intact  SNAP-25.  Band  densities  were 
quantitated and are represented graphically as the percentage of intact SNAP-25. 
 
Anti-BoNT/A antibodies do not enter cells, but instead inhibit SNAP-25 cleavage by preventing the 
entrance of BoNT/A into neurons, and so would not be expected to provide any efficacy if added  
post-intoxication.  Therefore,  to  confirm  that  the  observed  inhibition  mediated  by  NSC  95654  
post-intoxication  was  indeed  occurring  intracellularly,  anti-BoNT/A  neutralizing  antibodies  were 
tested in the post-intoxication assay. Whereas the simultaneous addition of neutralizing antibody and 
BoNT/A almost completely prevented the cleavage of SNAP-25, adding the antibody post-BoNT/A 
intoxication resulted in no detectable inhibition  of SNAP-25 cleavage  (Figure 4).  By comparison,  
30 µM NSC 95654 and NSC 104999 inhibited SNAP-25 cleavage regardless of whether the SMNPIs 
were added to the cells at the same time as BoNT/A, or only after the removal of extracellular toxin 
(i.e., post-intoxication) (Figure 4). Consistent with SMNPI potencies determined in vitro in the HPLC 
assay (Figure 1), NSC 95654 was more efficacious, with regard to inhibiting BoNT/A LC-mediated 
SNAP-25 cleavage in the neuronal cytosol, than NSC 104999.  Toxins 2011, 3                         
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Figure 3. Progressive SNAP-25 cleavage in neurons post-intoxication. Embryonic chick 
motor  neuron  cultures  were  incubated  for  1  h  in  10  nM  BoNT/A,  and  then  residual 
BoNT/A was removed by rinsing the cells three times with medium. Finally, the cells were 
collected for Western blot analysis at 1, 2, 3, 4, and 5 h after removal of extracellular  
(i.e., residual) BoNT/A. (A)  In the presence of medium alone, there was progressively 
more cleaved SNAP-25 (lower band) relative to intact SNAP-25 (upper band); (B) When 
NSC  95654  was  added  to  neurons  after  the  removal  of  residual  BoNT/A,  little  or  no 
change was apparent in the relative intensities of the bands corresponding to intact and 
cleaved SNAP-25. Graphs based on densitometry readings of Western blot bands show the 
means  and  standard  deviations  for  repeat  experiments  (N  =  4)  for  post-intoxication 
incubation  in  (C)  medium  alone  or  (D)  40  uM  NSC  95654.  By  5  h  after  removal  of 
residual BoNT/A by rinsing, a significantly lower percentage of SNAP-25 remained intact 
(P = 0.017, t-test, compared to 0 h) when the neurons were incubated in medium alone 
versus when incubated with 40 uM NSC 95654 (P = 0.595, t-test, compared to 0 h). 
 
Bafilomycin  A1  acts  as  an  inhibitor  by  preventing  the  endosomal  acidification  necessary  for 
translocation of BoNT/A from endosomes into the cytosol. Hence, it acts at a relatively early step in 
the intoxication process, but at a later step than anti-BoNT/A neutralizing antibodies (which block the 
binding  of  BoNT/A  to  neurons,  and  hence  prevent  entry  of  the  toxin).  Experiments  in  which 
Bafilomycin A1 was added at 20 min intervals, following 20 min intoxication with 10 nM BoNT/A 
(Figure 5) suggest that the majority of BoNT/A LC translocates from endosomes into the neuronal 
cytosol  approximately  30–90  min  after  toxin  exposure.  Therefore,  some  BoNT/A  LC  would  be 
expected  to  have  entered  the  neuronal  cytosol  after  1  h  incubation  with  BoNT/A.  Consequently, 
BoNT/A LC in the cytosol prior to Bafilomycin A1 addition would be expected to cleave SNAP-25 
throughout the remaining 5 h experimental period. Consistent with this hypothesis, the prevention of 
SNAP-25 cleavage observed when Bafilomycin A1 was present both during and after 1 h BoNT/A 
intoxication  was  significantly  decreased  when  Bafilomycin  A1  was  added  post-intoxication  Toxins 2011, 3                         
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(P < 0.001, t-test; Figure 4). In contrast, NSC 95654 and NSC 104999 are competitive inhibitors of the 
BoNT/A LC, and consequently can inhibit the enzyme’s catalytic activity regardless of how long after 
intoxication they are applied. Although there was a small decrease in inhibition of SNAP-25 cleavage 
when either NSC 95654 or NSC 104999 were added post-intoxication versus when the SMNPIs were 
also present during intoxication (Figure 4), the difference was not statistically significant (P = 0.109 
and P = 0.346 respectively, t-test). 
Figure 4. NSC 95654 and NSC 104999, but not BoNT/A neutralizing antibodies, inhibit 
the cleavage of SNAP-25 by internalized BoNT/A. Neurons were intoxicated with 10 nM 
BoNT/A for 1 h, rinsed thoroughly, and  collected 5 h later for Western blot analysis.  
(A) When BoNT/A neutralizing antibodies, Bafilomicin A1, NSC 95654, or NSC 104999 
were added to  neuronal cultures  during, as  well  as  after, incubation with  BoNT/A, all 
demonstrated  potent  inhibition  of  BoNT/A  LC-mediated  SNAP-25  cleavage.  However, 
neutralizing antibodies failed to protect BoNT/A-mediated SNAP-25 cleavage when added 
only  after  non-internalized  BoNT/A  was  removed.  In  contrast,  Bafilomycin  A1,  NSC 
95654,  and  NSC  104999  remained  effective  when  applied  post-intoxication;  (B)  Band 
densities  were  determined  from  the  Western  blot  results  and  graphed  as  means  and 
standard deviations from multiple experiments (N ≥ 4). Inhibitor treatments resulted in a 
significantly higher percentage of intact SNAP-25 (P < 0.001, t-test) versus when cells 
were intoxicated but untreated, except when neutralizing antibodies were applied only after 
intoxication (P = 0.500, t-test). 
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Figure  5.  Inhibitory  effects  of  Bafilomycin  A1  at  different  times  following  20  min 
exposure  of  chick  motor  neuron  cultures  to  10  nM  BoNT/A.  Cells  were  collected  for 
Western blot analysis 5 h after BoNT/A was removed. Maximal inhibition was observed 
when Bafilomycin A1 was present throughout the experiment, with hardly any difference if 
added immediately post-intoxication or at 20 min post-intoxication. The protective efficacy 
of Bafilomycin A1, with respect to SNAP-25 cleavage, decreased beginning at 40 min 
post-intoxication. No protection was detected after 100 min post-intoxication. These data 
suggest that it takes a minimum of 20 min and maximum of 100 min until the BoNT/A LC 
translocates from the endosome to the cytosol. Because Bafilomycin A1 is a reversible 
inhibitor of vacuolar-type H
+-ATPase, the decrease in SNAP-25 cleavage observed when 
Bafilomycin was present only during intoxication is likely due to a delay in BoNT/A LC 
cytosol  entry.  Medians  and  standard  errors  were  calculated  based  on  a  minimum  
of 6 experiments. 
 
4. Conclusions 
The ability to enter neurons and inhibit BoNT/A post-intoxication is imperative for any SMNPI of 
BoNT/A LC enzymatic activity if it is to be an effective treatment for the paralysis resulting from 
toxin-mediated SNARE protein cleavage. By administering SMNPIs after exposing embryonic chick 
motor neurons to BoNT/A for 1 h, the results from this study demonstrate that NSC 95654 and NSC 
104999  possess  the  ability  to  inhibit  BoNT/A  post-intoxication  within  the  neuronal  cytosol.  The 
demonstration of this attribute reinforces the hypothesis that SMNPIs can potentially be employed as 
therapeutics to treat botulism, and will complement antitoxin administration by inhibiting BoNT/A that 
is  inaccessible  to  antibodies  (i.e.,  BoNT/A  in  the  neuronal  cytosol).  Indeed,  the  post-intoxication 
efficacies  of  NSC  95654  and  NSC  104999  indicate  that  these  SMNPIs  represent  a  promising Toxins 2011, 3                         
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chemotype for therapeutic development. Although methods have been developed to test the ability of 
inhibitors to reduce time to recovery after local injection of BoNT  in vivo [17], the paradigm for 
testing post-intoxication efficacy in cell culture that we have presented here is a relatively simple way 
of confirming intracellular, post-intoxication, efficacy of inhibitors prior to testing in animals. 
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